Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

Phase I Clinical Trial of Safety, Tolerance and Immunogenicity of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

phase I study will evaluate the safety and tolerability of GEN2-Recombinant COVID-19 Vaccine (CHO cells) in healthy people aged 18 years and older.

A total of 234 subjects were enrolled, of which 126 were enrolled in the 18-59-year-old group, and were randomly assigned to receive experimental vaccine 1, experimental vaccine 2, experimental vaccine 3 and placebo in a ratio of 2:2:2:1; 60- A total of 54 people were enrolled in the 69-year-old and ≥70-year-old groups, and were randomly assigned to receive the experimental vaccine 1 and placebo according to the ratio of 2:1.

Study Overview

• Status: Completed
• Conditions: COVID-19 Pneumonia
• Intervention / Treatment: Biological: Experimental Vaccine 1; Biological: Experimental Vaccine 2; Biological: Experimental Vaccine 3; Biological: placebo

• Study Type: Interventional
• Enrollment (Actual): 234
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Henan
    • Shangqiu, Henan, China
      • Ning ling Center for Disease Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age range: healthy people aged 18 and above, who can provide legal identification;
• No history of t SARS-CoV-2 vaccination;
• Able to provide a negative nucleic acid test certificate for the new coronavirus within 48 hours;
• Have the ability to understand (if illiterate, a fair witness is required to accompany the informed consent) research procedures, have informed consent, voluntarily sign the informed consent form, and be able to comply with the requirements of the clinical research protocol；
• Inquire about medical history and physical examination, and the investigator judges that the health status is good;
• Females of childbearing age (menarche to menopause) were not pregnant (negative urine pregnancy test) at enrollment, were not breastfeeding, and had no reproductive plans within the first 6 months after enrollment and took effective contraceptive measures; 2 weeks prior to enrollment have taken effective contraceptive measures;
• Able and willing to complete the entire prescribed study plan throughout the study follow-up period.

Exclusion Criteria:

First-dose exclusion criteria：

• Confirmed cases, suspected cases, asymptomatic infections, or close contacts of the above-mentioned groups of SARS-CoV-2 infection (check "China Disease Prevention and Control Information System");
• Axillary body temperature ≥37.3℃ before vaccination;
• Positive test for novel coronavirus antibody (IgG+IgM);
• Have a history of SARS virus infection (self-report, on-site inquiry);
• Fever (axillary temperature ≥37.3℃), dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, and dyspnea within 14 days before vaccination;
• The test results of blood biochemistry, blood routine, urine routine and coagulation function-related indexes before vaccination are abnormal, which are beyond the reference value range and have clinically significant abnormalities;
• Severe allergic reactions (such as acute allergic reactions, urticaria, skin eczema, dyspnea, angioedema or abdominal pain) have occurred in the past;
• Allergy to any component of the study vaccine (such as: aluminum, histidine, etc.);
• Patients with convulsions, epilepsy, encephalopathy or other progressive neurological diseases (such as transverse myelitis, Guillain-Barre syndrome, demyelinating diseases, etc.), long-term history of alcohol and drug abuse, history of thyroidectomy, infectious diseases, mental illness medical or family history;
• Known or suspected diseases include: severe respiratory disease, severe liver and kidney disease, severe cardiovascular disease, uncontrolled hypertension (systolic blood pressure ≥140mmHg, diastolic blood pressure ≥90mmHg), diabetic complications, malignant tumors, Various acute diseases, acute exacerbations of chronic diseases or severe chronic diseases;
• Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
• Thrombocytopenia, history of abnormal coagulation function (such as coagulation factor deficiency, coagulation disease);
• Asplenia or splenectomy, functional asplenia caused by any circumstance;
• Are receiving anti-TB (tuberculosis) treatment;
• Received immune enhancement or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days);
• Received live attenuated vaccine within 28 days before vaccination, and received other vaccines within 14 days before vaccination;
• Received blood products within 3 months before vaccination;
• Received other study drugs within 6 months before vaccination;
• Planning to move before the end of the study or to be away from the local area for an extended period of time during a scheduled study visit;
• The investigator judges other circumstances that are not suitable to participate in this clinical trial.

Exclusion criteria for second and third doses：

• Positive urine pregnancy test;
• Patients with abnormal conditions such as high fever (axillary temperature ≥39.0℃) for three days, convulsions, severe allergic reactions or any adverse reactions of the --Nervous system after the previous dose of vaccination;
• Serious adverse reactions that are causally related to the previous dose of vaccination;
• For those newly discovered or newly discovered after the previous dose of vaccine that do not meet the first-dose inclusion criteria or meet the first-dose exclusion criteria, the investigator will determine whether to continue participating in the study;
• Other reasons for exclusion considered by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: placebo group	Biological: placebo; Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
Experimental: Experimental group 1	Biological: Experimental Vaccine 1; Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
Experimental: Experimental group 2	Biological: Experimental Vaccine 2; Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
Experimental: Experimental group 3	Biological: Experimental Vaccine 3; Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The incidence rate of any adverse reactions/events	within 30 minutes after vaccination
The incidence severity of any adverse reactions/events	within 30 minutes after vaccination
The incidence rate of solicited adverse reactions/events	within 0-7 days after vaccination
The incidence severity of solicited adverse reactions/events	within 0-7 days after vaccination
The incidence rate of solicited adverse reactions/events	within 8-30 days after vaccination
The incidence of SAE observed	up to 12 months after full course of immunization
The incidence of AESI observed	up to 12 months after full course of immunization
the incidence of abnormal blood biochemistry, blood routine, blood coagulation function and urine routine	on the 4th day after each dose of vaccination
The incidence severity of solicited adverse reactions/events	within 8-30 days after vaccination
Incidence of adverse events leading to withdrawal	within 8-30 days after vaccination
Severity of adverse events leading to withdrawal	within 8-30 days after vaccination
Neutralizing antibody level against SARS-CoV-2 GMT	Day 15th, 30th, 90th, 180th, 270th, 360th after full course of immunization
Neutralizing antibody level against SARS-CoV-2 IgG antibody GMC	Day 15th, 30th, 90th, 180th, 270th, 360th after full course of immunization
Neutralizing antibody level against SARS-CoV-2 positive rate	Day 15th, 30th, 90th, 180th, 270th, 360th after full course of immunization
Neutralizing antibody level against SARS-CoV-2 Positive conversion rate	Day 15th, 30th, 90th, 180th, 270th, 360th after full course of immunization

Secondary Outcome Measures

Outcome Measure	Time Frame
GMT of GEN2-Recombinant COVID-19 Vaccine (CHO cells, NVSI-06-08) against VOC in healthy people aged 18 and above	after the full course of immunization
Cellular immune response level of subjects aged 18-59	Before the first vaccination ， 15 days after the full course of immunization

Collaborators and Investigators

• Sponsor: National Vaccine and Serum Institute, China
• Collaborators: Beijing Institute of Biological Products Co Ltd.; Lanzhou Institute of Biological Products Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): June 18, 2022
• Primary Completion (Actual): February 28, 2024
• Study Completion (Actual): February 28, 2024

Study Registration Dates

• First Submitted: June 5, 2022
• First Submitted That Met QC Criteria: June 5, 2022
• First Posted (Actual): June 7, 2022

Study Record Updates

• Last Update Posted (Estimated): January 16, 2026
• Last Update Submitted That Met QC Criteria: January 15, 2026
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: COVID-19
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; COVID-19; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: CXSL2200156-Ⅰ

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No